Previously, our laboratory and other groups have also shown that targeting CXCR2 in cancer cells as well as in the host leads to enhanced chemotherapeutic response [8,9,14], inhibition of tumor growth, angiogenesis [15,16], and metastasis [17] in different cancer types indicating CXCR2 as an emerging target for cancer therapy [18,19]. This evidence concerns the gene CXCR2 and neoplasm.